
John P Kowalski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2559184/publications.pdf Version: 2024-02-01



IOHN P KOWALSKI

#	Article	IF	CITATIONS
1	Pharmacokinetics, metabolism and off-target effects in the rat of 8-[(1H-) Tj ETQq1 1 0.784314 rgBT /Overlock 10 as a potential augmenting pathway for inhibition. Xenobiotica, 2021, 51, 901-915.		' Td (benz <mark>o</mark> 1
2	Massively parallel characterization of CYP2C9 variant enzyme activity and abundance. American Journal of Human Genetics, 2021, 108, 1735-1751.	6.2	53
3	Novel insights into oxidation of fatty acids and fatty alcohols by cytochrome P450 monooxygenase CYP4B1. Archives of Biochemistry and Biophysics, 2020, 679, 108216.	3.0	9
4	Heterologous Expression and Functional Characterization of Novel CYP2C9 Variants Identified in the Alaska Native People. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 233-240.	2.5	5
5	Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1. Journal of Medicinal Chemistry, 2020, 63, 4824-4836.	6.4	15
6	Structure–Activity Relationships for CYP4B1 Bioactivation of 4-Ipomeanol Congeners: Direct Correlation between Cytotoxicity and Trapped Reactive Intermediates. Chemical Research in Toxicology, 2019, 32, 2488-2498.	3.3	7
7	Influence of Stereochemistry on the Bioactivation and Glucuronidation of 4-Ipomeanol. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 308-316.	2.5	4
8	Expression and Functional Characterization of Breast Cancer-Associated Cytochrome P450 4Z1 in <i>Saccharomyces cerevisiae</i> . Drug Metabolism and Disposition, 2017, 45, 1364-1371.	3.3	35
9	Ligand characterization of CYP4B1 isoforms modified for high-level expression in <i>Escherichia coli</i> and HepG2 cells. Protein Engineering, Design and Selection, 2017, 30, 205-216.	2.1	13